Thursday 27 Feb
Tenth of Ramadan for Pharmaceutical Industries and Diagnostic Reagents (Rameda) has announced a proposal to increase its issued capital, to be presented to the Extraordinary General Assembly.
According to a Wednesday disclosure, the proposed increase is from EGP 375.86 million to EGP 377.74 million, representing a rise of EGP 1.88 million.
This will be accomplished through the issuance of new
shares, specifically for the company's employee incentive and reward program,
with funding sourced from beneficiary payments.
Rameda's financial results for the first nine months of 2024 show profits of EGP 244.03 million (compared to EGP 196.97 million in 2023) and revenues of EGP 1.78 billion (up from EGP 1.38 billion in 2023).
